HK1046854B - 用於控制絕經熱潮紅的降鈣素基因有關肽的拮抗劑及其釋出的抑制劑 - Google Patents

用於控制絕經熱潮紅的降鈣素基因有關肽的拮抗劑及其釋出的抑制劑 Download PDF

Info

Publication number
HK1046854B
HK1046854B HK02108347.1A HK02108347A HK1046854B HK 1046854 B HK1046854 B HK 1046854B HK 02108347 A HK02108347 A HK 02108347A HK 1046854 B HK1046854 B HK 1046854B
Authority
HK
Hong Kong
Prior art keywords
piperidinyl
carbonyl
dihydro
dibromo
amino
Prior art date
Application number
HK02108347.1A
Other languages
English (en)
Chinese (zh)
Other versions
HK1046854A1 (en
Inventor
亨利‧杜兹
亨利‧杜茲
克劳斯‧鲁道夫
沃尔夫冈‧埃伯莱因
克勞斯‧魯道夫
沃尔夫哈德‧恩格尔
沃爾夫岡‧埃伯萊因
沃爾夫哈德‧恩格爾
Original Assignee
贝林格尔英格海姆法玛两合公司
貝林格爾英格海姆法瑪兩合公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 贝林格尔英格海姆法玛两合公司, 貝林格爾英格海姆法瑪兩合公司 filed Critical 贝林格尔英格海姆法玛两合公司
Publication of HK1046854A1 publication Critical patent/HK1046854A1/xx
Publication of HK1046854B publication Critical patent/HK1046854B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/22—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of calcitonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK02108347.1A 1999-08-10 2000-08-05 用於控制絕經熱潮紅的降鈣素基因有關肽的拮抗劑及其釋出的抑制劑 HK1046854B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19937304A DE19937304C2 (de) 1999-08-10 1999-08-10 Verwendung von CGRP-Antagonisten zur Bekämpfung menopausaler Hitzewallungen
DE19937304.3 1999-08-10
PCT/EP2000/007613 WO2001010425A2 (de) 1999-08-10 2000-08-05 Verwendung von cgrp-antagonisten und cgrp-release-hemmern zur bekämpfung menopausaler hitzewallungen

Publications (2)

Publication Number Publication Date
HK1046854A1 HK1046854A1 (en) 2003-01-30
HK1046854B true HK1046854B (zh) 2005-02-25

Family

ID=7917551

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02108347.1A HK1046854B (zh) 1999-08-10 2000-08-05 用於控制絕經熱潮紅的降鈣素基因有關肽的拮抗劑及其釋出的抑制劑

Country Status (32)

Country Link
EP (1) EP1207884B1 (https=)
JP (1) JP2003506403A (https=)
KR (1) KR100713573B1 (https=)
CN (1) CN1166361C (https=)
AR (1) AR025078A1 (https=)
AT (1) ATE281168T1 (https=)
AU (1) AU777709B2 (https=)
BG (1) BG65366B1 (https=)
BR (1) BR0013009A (https=)
CA (1) CA2378428C (https=)
CZ (1) CZ300513B6 (https=)
DE (2) DE19937304C2 (https=)
EA (1) EA007531B1 (https=)
EE (1) EE04928B1 (https=)
ES (1) ES2231243T3 (https=)
HK (1) HK1046854B (https=)
HR (1) HRP20020117A2 (https=)
HU (1) HUP0202397A3 (https=)
IL (1) IL148057A (https=)
MX (1) MXPA02001373A (https=)
MY (1) MY129668A (https=)
NO (1) NO20020605D0 (https=)
NZ (1) NZ517367A (https=)
PL (1) PL198483B1 (https=)
PT (1) PT1207884E (https=)
SK (1) SK285587B6 (https=)
TR (1) TR200200359T2 (https=)
TW (1) TWI285550B (https=)
UA (1) UA73137C2 (https=)
WO (1) WO2001010425A2 (https=)
YU (1) YU8302A (https=)
ZA (1) ZA200200997B (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19952147A1 (de) 1999-10-29 2001-05-03 Boehringer Ingelheim Pharma Neue Cyclopropane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE10139410A1 (de) * 2001-08-17 2003-02-27 Boehringer Ingelheim Pharma Verwendung von BIBN4096 in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne
WO2003050109A1 (en) * 2001-12-12 2003-06-19 Eli Lilly And Company Alanyl-piperidine heterocyclic derivatives useful against cardiovascular diseases
DE10206770A1 (de) * 2002-02-19 2003-08-28 Boehringer Ingelheim Pharma Verfahren zur Herstellung eines Pulverinhalativums enthaltend ein Salz des CGRP-Antagonisten BIBN4096
US6900317B2 (en) 2002-02-19 2005-05-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Salts of the CGRP antagonist BIBN4096 and inhalable powdered medicaments containing them
DE10207026A1 (de) * 2002-02-20 2003-08-28 Boehringer Ingelheim Kg Pulverinhalativum, enthaltend den CGRP-Antagonisten BIBN4096 und Verfahren zu dessen Herstellung
DE10227294A1 (de) * 2002-06-19 2004-01-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Zubereitungen zur intranasalen Applikation ausgewählter, von Aminosäuren abgeleiteter CGRP-Antagonisten sowie Verfahren zu deren Herstellung
DE10250080A1 (de) * 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7595312B2 (en) 2002-10-25 2009-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
DE10300973A1 (de) * 2003-01-14 2004-07-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Carbonsäuren und deren Ester, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
WO2005004869A1 (en) * 2003-07-07 2005-01-20 Boehringer Ingelheim International Gmbh Use of cgrp antagonists in treatment and prevention of hot flushes in prostate cancer patients
CN100418948C (zh) * 2003-07-15 2008-09-17 麦克公司 羟基吡啶cgrp受体抗拮抗剂
DE10338399A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Mikropartikel, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-Iysyl]-4-(4-pyridinyl)-piperazin, Verfahren zu deren Herstellung sowie deren Verwendung als Inhalaltionspulver
DE102004015723A1 (de) 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7696195B2 (en) 2004-04-22 2010-04-13 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
DE102004019492A1 (de) * 2004-04-22 2005-11-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102004063755A1 (de) * 2004-12-29 2006-07-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von CGRP-Antagonisten zur Behandlung und Vorbeugung von Hitzewallungen bei Patienten mit Prostatakrebs
DE102004063752A1 (de) * 2004-12-29 2006-07-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung ausgewählter CGRP-Antagonisten zur Bekämpfung menopausaler Hitzewallungen
EP1770091A1 (de) 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7491717B2 (en) 2005-03-23 2009-02-17 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
US7439237B2 (en) 2005-04-15 2008-10-21 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2132855T3 (es) * 1995-09-07 1999-08-16 Oreal Extracto de iridaceas y composiciones que lo contienen.
US5910482A (en) * 1996-03-19 1999-06-08 Board Of Regents, The University Of Texas System Treatment or prevention of preeclampsia, eclampsia with calcitonin gene related peptide, CGRP analog, progestational agent, nitric oxide source, and cyclooxygenase inhibitor
US5710024A (en) * 1996-07-23 1998-01-20 Smithkline Beecham Corporation Polynucleotides that encode the calcitonin gene-related peptide receptor coponent factor (HOUNDC44)
DE59711622D1 (de) * 1996-09-10 2004-06-17 Boehringer Ingelheim Pharma Abgewandelte aminosäuren, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE19911039A1 (de) * 1999-03-12 2000-09-14 Boehringer Ingelheim Pharma Abgewandelte Aminosäureamide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung

Also Published As

Publication number Publication date
CZ2002497A3 (cs) 2002-06-12
JP2003506403A (ja) 2003-02-18
EE04928B1 (et) 2007-12-17
AU6992800A (en) 2001-03-05
HK1046854A1 (en) 2003-01-30
TR200200359T2 (tr) 2002-05-21
WO2001010425A2 (de) 2001-02-15
SK285587B6 (sk) 2007-04-05
ES2231243T3 (es) 2005-05-16
EP1207884B1 (de) 2004-11-03
KR100713573B1 (ko) 2007-05-02
UA73137C2 (en) 2005-06-15
DE50008527D1 (de) 2004-12-09
CZ300513B6 (cs) 2009-06-03
AR025078A1 (es) 2002-11-06
EA200200207A1 (ru) 2002-08-29
HUP0202397A2 (en) 2002-10-28
ZA200200997B (en) 2002-10-30
CN1166361C (zh) 2004-09-15
MXPA02001373A (es) 2002-07-30
IL148057A0 (en) 2002-09-12
TWI285550B (en) 2007-08-21
NO20020605L (no) 2002-02-07
NO20020605D0 (no) 2002-02-07
DE19937304A1 (de) 2001-03-15
MY129668A (en) 2007-04-30
SK1972002A3 (en) 2002-06-04
PT1207884E (pt) 2004-12-31
CA2378428C (en) 2009-10-20
PL364049A1 (en) 2004-12-13
CA2378428A1 (en) 2001-02-15
AU777709B2 (en) 2004-10-28
BR0013009A (pt) 2002-04-30
PL198483B1 (pl) 2008-06-30
EP1207884A2 (de) 2002-05-29
KR20020016947A (ko) 2002-03-06
YU8302A (sh) 2004-12-31
EE200200061A (et) 2003-04-15
BG65366B1 (bg) 2008-04-30
CN1370069A (zh) 2002-09-18
EA007531B1 (ru) 2006-10-27
HRP20020117A2 (en) 2003-10-31
WO2001010425A3 (de) 2002-02-07
DE19937304C2 (de) 2003-08-21
IL148057A (en) 2008-04-13
BG106391A (bg) 2002-09-30
ATE281168T1 (de) 2004-11-15
NZ517367A (en) 2004-09-24
HUP0202397A3 (en) 2006-07-28

Similar Documents

Publication Publication Date Title
CN1166361C (zh) 用于控制绝经热潮红的降钙素基因有关肽的拮抗剂及其释出的抑制剂
CN1247588C (zh) 腺苷A2a受体拮抗剂
CN1232462A (zh) 毒蕈碱拮抗剂
CN1100535C (zh) 用于治疗呕吐的药剂
HK1046102A1 (zh) 用雌激素激动剂/拮抗剂治疗某些癌症的方法
CN1788000A (zh) 酞嗪酮衍生物
CN1091314A (zh) 含有降钙素的药物组合物
CN1596258A (zh) 腺A2α受体拮抗剂
CN1177844C (zh) 作为cgrp拮抗剂的新环丙烷、包含该化合物的药物及其生产方法
CN1483025A (zh) 化合物
CN1688581A (zh) [1,2,4]－三唑二环腺苷A2ａ受体拮抗剂
CN1501934A (zh) 新型的3-c(o)r取代的10-环己基苯甲酰基吡咯并苯并二氮杂�;保胎催产素受体拮抗剂
CN1030587A (zh) 2-(杂环烷基)咪唑并吡啶
CN1018614B (zh) 制备含n-杂环基-4-哌啶胺类的抗组胺组合物的方法
CN1300281A (zh) 具有释放生长激素特性的化合物
CN1136852C (zh) 头孢克罗的制药用配方
CN1921859A (zh) 用于治疗骨疾病的吲哚衍生物
CN1543347A (zh) Bibn4096与其它抗偏头痛药物组合对治疗偏头痛的用途
CN1805749A (zh) 星孢素衍生物的新药物用途
CN101076333A (zh) 可用于治疗TNF－α和IL－1介导的疾病的吡唑并杂芳基化合物
CN101039678A (zh) 用于治疗认知障碍的咪唑并[1,5－a]三唑并[1,5－d]苯并二氮杂䓬衍生物
CN1178923C (zh) 1,4-二氮杂环庚烷-2,5-二酮衍生物及其作为nk-1受体拮抗剂的应用
CN101035537A (zh) 治疗眼部疾病的组合物和方法
CN1220490C (zh) 哌嗪环氧乙烷衍生物在制备用于诱导肿瘤细胞死亡的药物中的应用
CN1507449A (zh) 1-氧杂-3,9-二氮杂-螺[5.5]十一-2-酮衍生物及其作为神经激肽受体拮抗剂的用途

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20100805